Page 86 - Read Online

Aguiar. Rare Dis Orphan Drugs J 2024;3:13 https://dx.doi.org/10.20517/rdodj.2023.56 Page 27 of 29

levels with markers of renal function in patients with Fabry disease. Clin Chim Acta 2018;478:62-7. DOI PubMed
187. Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001;24:66-70; discussion 65.
DOI
188. Sessa A, Meroni M, Battini G, et al. Renal involvement in Anderson-Fabry disease. J Nephrol 2003;16:310-3. PubMed
189. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002;13:S134-8. DOI PubMed
190. Fischer EG, Moore MJ, Lager DJ. Fabry disease: a morphologic study of 11 cases. Mod Pathol 2006;19:1295-301. DOI PubMed
191. Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the international study group of
Fabry nephropathy (ISGFN). Nephrol Dial Transplant 2010;25:2168-77. DOI PubMed PMC
192. Ortiz A, Oliveira J, Cianciaruso B, Waldek S, Wanner C. The Fabry registry demonstrates heterogeneity of renal progression in 883
males and females with Fabry disease. Nephrol Dial Transplant 2006;21:iv4. Available from: https://www.researchgate.net/
publication/295740917_The_Fabry_registry_demonstrates_heterogeneity_of_renal_progression_in_833_males_and_females_with_
Fabry_disease [Last accessed on 19 Apr 2024].
193. Skrunes R, Tøndel C, Leh S, et al. Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc
Nephrol 2017;12:1470-9. DOI PubMed PMC
194. Santostefano M, Cappuccilli M, Gibertoni D, et al. Fabry disease nephropathy: histological changes with nonclassical mutations and
genetic variants of unknown significance. Am J Kidney Dis 2023;82:581-96.e0. DOI
195. Azevedo O, Gago MF, Miltenberger-Miltenyi G, et al. Natural history of the late-onset phenotype of Fabry disease due to the p.
F113L mutation. Mol Genet Metab Rep 2020;22:100565. DOI PubMed PMC
196. Azevedo E, Mendes A, Seixas D, et al. Functional transcranial Doppler: presymptomatic changes in Fabry disease. Eur Neurol
2012;67:331-7. DOI
197. Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI
retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1249-54. DOI
198. Zhao Y, Zhu Y, Li F, et al. Brain MRI correlations with disease burden and biomarkers in Fabry disease. J Neurol 2023;270:4939-48.
DOI PubMed PMC
199. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.
Neurology 1998;50:1746-9. DOI
200. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with
Fabry disease. Neurology 2005;65:600-2. DOI PubMed
201. Steinicke R, Gaertner B, Grittner U, et al. Kidney function and white matter disease in young stroke patients: analysis of the stroke in
young Fabry patients study population. Stroke 2012;43:2382-8. DOI
202. Körver S, Vergouwe M, Hollak CEM, van Schaik IN, Langeveld M. Development and clinical consequences of white matter lesions
in Fabry disease: a systematic review. Mol Genet Metab 2018;125:205-16. DOI PubMed
203. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white
matter lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448-56. DOI PubMed
204. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry
disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013;8:47. DOI PubMed PMC
205. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme
replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis
2014;37:341-52. DOI PubMed
206. Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke
2015;46:302-13. DOI
207. Underhill HR, Golden-Grant K, Garrett LT, Uhrich S, Zielinski BA, Scott CR. Detecting the effects of Fabry disease in the adult
human brain with diffusion tensor imaging and fast bound-pool fraction imaging. J Magn Reson Imaging 2015;42:1611-22. DOI
PubMed PMC
208. Ulivi L, Kanber B, Prados F, et al. White matter integrity correlates with cognition and disease severity in Fabry disease. Brain
2020;143:3331-42. DOI
209. Lyndon D, Davagnanam I, Wilson D, et al. MRI-visible perivascular spaces as an imaging biomarker in Fabry disease. J Neurol
2021;268:872-8. DOI PubMed PMC
210. Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients.
Cerebrovasc Dis 2011;31:294-9. DOI
211. Uçeyler N, Homola GA, Guerrero González H, et al. Increased arterial diameters in the posterior cerebral circulation in men with
Fabry disease. PLoS One 2014;9:e87054. DOI PubMed PMC
212. Politei J, Schenone AB, Burlina A, et al. Vertebrobasilar dolichoectasia in Fabry disease: the earliest marker of neurovascular
involvement? J Inborn Errors Metab Scr 2014;2:232640981454124. DOI
213. Takanashi JI, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S. T1 hyperintensity in the pulvinar: key imaging feature for
diagnosis of Fabry disease. AJNR Am J Neuroradiol 2003;24:916-21. PubMed
214. Burlina AP, Manara R, Caillaud C, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol
2008;255:738-44. DOI
215. Fellgiebel A, Wolf DO, Kolodny E, Müller MJ. Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. J